Nesrin Karamustafalioglu1, Abdullah Genc1, Tevfik Kalelioglu1, Akif Tasdemir2, Gokhan Umut1, Said Incir3, Mustafa Akkuş1, Murat Emul4. 1. Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey. 2. Department of Psychiatry, Bakırkoy Mental Health Research and Training State Hospital, Istanbul, Turkey akiftasdemir@mail.com. 3. Department of Biochemistry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey. 4. Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, Istanbul, Turkey.
Abstract
BACKGROUND: Inconsistent findings concerning brain-derived neurotrophic factor (BDNF) levels across different episodes in bipolar disorder have been reported, which is also in line with the treatment effects on BDNF levels in acute mania. We aimed to compare plasma BDNF level alterations after pure antipsychotic drug or ECT plus antipsychotic drug treatment in acute mania. METHODS: Sixty-eight patients with mania were divided into two treatment arms: the antipsychotic treatment arm (AP) and electroconvulsive therapy (ECT)+AP arm. In addition, 30 healthy controls were included in the study. RESULTS: There was no significant statistical difference according to mean age, education level, marital and working status between patients and healthy controls. The initial serum BDNF level in patients with acute mania was significantly lower than healthy controls. The initial BDNF level between the ECT arm and AP arm was not significant. The BDNF level decreased significantly after reaching remission in patients with acute mania. The change in BDNF level in the AP arm was not significant while in the ECT arm it was significant after treatment. CONCLUSIONS: In this study, for the first time we revealed a significant decrease in BDNF levels after ECT sessions in acute manic patients. Besides clinical remission after treatment in acute mania, the decrement in BDNF levels does not seem to be related to clinical response. Thus cumulative effects of mood episodes for the ongoing decrease in BDNF levels might be borne in mind despite the achievement of remission and/or more time being required for an increase in BDNF levels after treatment.
BACKGROUND: Inconsistent findings concerning brain-derived neurotrophic factor (BDNF) levels across different episodes in bipolar disorder have been reported, which is also in line with the treatment effects on BDNF levels in acute mania. We aimed to compare plasma BDNF level alterations after pure antipsychotic drug or ECT plus antipsychotic drug treatment in acute mania. METHODS: Sixty-eight patients with mania were divided into two treatment arms: the antipsychotic treatment arm (AP) and electroconvulsive therapy (ECT)+AP arm. In addition, 30 healthy controls were included in the study. RESULTS: There was no significant statistical difference according to mean age, education level, marital and working status between patients and healthy controls. The initial serum BDNF level in patients with acute mania was significantly lower than healthy controls. The initial BDNF level between the ECT arm and AP arm was not significant. The BDNF level decreased significantly after reaching remission in patients with acute mania. The change in BDNF level in the AP arm was not significant while in the ECT arm it was significant after treatment. CONCLUSIONS: In this study, for the first time we revealed a significant decrease in BDNF levels after ECT sessions in acute manicpatients. Besides clinical remission after treatment in acute mania, the decrement in BDNF levels does not seem to be related to clinical response. Thus cumulative effects of mood episodes for the ongoing decrease in BDNF levels might be borne in mind despite the achievement of remission and/or more time being required for an increase in BDNF levels after treatment.
Authors: Brisa S Fernandes; Marc L Molendijk; Cristiano A Köhler; Jair C Soares; Cláudio Manuel G S Leite; Rodrigo Machado-Vieira; Thamara L Ribeiro; Jéssica C Silva; Paulo M G Sales; João Quevedo; Viola Oertel-Knöchel; Eduard Vieta; Ana González-Pinto; Michael Berk; André F Carvalho Journal: BMC Med Date: 2015-11-30 Impact factor: 8.775
Authors: Tobias Rowland; Benjamin I Perry; Rachel Upthegrove; Nicholas Barnes; Jayanta Chatterjee; Daniel Gallacher; Steven Marwaha Journal: Br J Psychiatry Date: 2018-09 Impact factor: 9.319